All-In with Chamath, Jason, Sacks & Friedberg cover image

E43: Innovative venture strategies, Zymergen's implosion, Square acquires Afterpay, future of fintech & more

All-In with Chamath, Jason, Sacks & Friedberg

00:00

The Rise and Fall of Zymergen

This chapter critically analyzes Zymergen's financial struggles post-IPO, contrasting its initial promise with significant issues in its product pipeline and leadership changes. The discussion expands to the broader synthetic biology sector, exploring the pitfalls of over-funding ventures lacking product-market fit and the dangerous allure of narrative-driven investing. Additionally, it emphasizes the necessity for rigorous due diligence and the importance of core metrics when evaluating emerging tech companies.

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app